Clinical Trial: Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring

U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07897526) titled 'Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring' on Sept. 28.

Brief Summary: Heart transplantation (HTx) remains the gold-standard treatment for patients with end-stage heart failure refractory to the medical management, offering the best survival and quality of life.

In the absence of a reliable non-invasive biomarker, international guidelines recommend to screen for cardiac allograft rejection during the first-year post-transplant using iterative protocol endomyocardial biopsies, a stressful and invasive procedure at risk of periprocedural complications. Th...